Artículos de revistas
Optimal Duration Of Androgen Deprivation Therapy Following Radiation Therapy In Intermediate- Or High-risk Non-metastatic Prostate Cancer: A Systematic Review And Meta-analysis
Registro en:
Optimal Duration Of Androgen Deprivation Therapy Following Radiation Therapy In Intermediate- Or High-risk Non-metastatic Prostate Cancer: A Systematic Review And Meta-analysis. Brazilian Soc Urol, v. 41, p. 425-434 MAY-JUN-2015.
1677-5538
WOS:000360017900007
10.1590/S1677-5538.IBJU.2014.0412
Autor
Leal
Frederico; Novis de Figueiredo
Maximiliano Augusto; Sasse
Andre Deeke
Institución
Resumen
Objectives: To investigate current evidence on the optimal duration of adjuvant hormone deprivation for prostate cancer treated with radiation therapy with curative intent. Materials and Methods: A systematic search was performed in electronic databases. Data from randomized trials comparing different durations of hormone blockade was collected for pooled analysis. Overall survival, disease-free survival, disease-specific survival and toxicity were the outcomes of interest. Meta-analyses were performed using random-effects model. Results: Six studies met the eligibility criteria. For overall survival, the pooled data from the studies demonstrated a statistically significant benefit for longer hormone deprivation (Hazard Ratio 0.84; 95% CI 0.74 - 0.96). A statistically significant benefit was also found for disease-free survival (Hazard Ratio 0.74; 95% CI 0.62 - 0.89), and disease-specific survival (Hazard Ratio 0.73; 95% CI 0.62 - 0.85). Studies with longer blockade duration arm demonstrated greater benefit. Toxicity was low, with no increase in cardiovascular events. Conclusions: Longer duration of androgen deprivation combined to radiotherapy prolongs OS, DFS and DSS in patients with intermediate and high-risk non-metastatic prostate cancer. However, this evidence is based on trials using older radiation techniques, and further research of combination of androgen deprivation and new RT technologies may be warranted. 41 3
425 434